The National Institute for Health and Care Excellence (NICE) faced "difficult decisions" when it deemed a breast cancer drug which can extend sufferers lives by "up to six months" was too expensive, according to a health expert.
Dr Hilary Jones told Daybreak the £90,000 price tag per patient would have meant taking funds away from other vital services the NHS provides.
More top news
The UK economy grew by 0.3% during the second quarter of 2017, up from 0.2% in the first three months of the year.
A teenage girl has been charged with terror offences after allegedly arranging with an IS fighter to receive weapons for a UK attack.
Congress has voted overwhelmingly to impose new sanctions against Russia - and curb Donald Trump's ability to waive the penalties.